ORIC Pharmaceuticals (ORIC) Financials

$5.07 -0.10 (-1.93%)

As of 01:37 PM Eastern

Annual Income Statements for ORIC Pharmaceuticals

This table shows ORIC Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-89	-101	-128
Consolidated Net Income / (Loss)	-89	-101	-128
Net Income / (Loss) Continuing Operations	-89	-101	-128
Total Pre-Tax Income	-89	-101	-128
Total Operating Income	-92	-111	-143
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	92	111	143
Selling, General & Admin Expense	25	26	29
Research & Development Expense	67	85	114
Total Other Income / (Expense), net	2.65	10	15
Basic Earnings per Share	($2.25)	($1.96)	($1.83)
Weighted Average Basic Shares Outstanding	39.66M	51.45M	69.73M
Diluted Earnings per Share	($2.25)	($1.96)	($1.83)
Weighted Average Diluted Shares Outstanding	39.66M	51.45M	69.73M
Weighted Average Basic & Diluted Shares Outstanding	45.09M	67.38M	71.03M

This table shows ORIC Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-25	-21	-24	-23	-25	-28	-25	-32	-34	-37
Consolidated Net Income / (Loss)	-25	-21	-24	-23	-25	-28	-25	-32	-35	-36
Net Income / (Loss) Continuing Operations	-25	-21	-24	-23	-25	-28	-25	-32	-35	-36
Total Pre-Tax Income	-25	-21	-24	-23	-25	-28	-25	-32	-35	-36
Total Operating Income	-26	-22	-26	-25	-29	-31	-29	-36	-38	-40
Total Operating Expenses	26	22	26	25	29	31	29	36	38	40
Selling, General & Admin Expense	5.97	5.82	6.16	6.21	6.29	6.95	7.03	7.08	7.12	7.60
Research & Development Expense	20	16	20	19	22	24	22	29	31	32
Total Other Income / (Expense), net	0.87	1.27	1.73	2.05	3.20	3.10	3.98	4.05	3.75	3.26
Basic Earnings per Share	($0.63)	($0.52)	($0.53)	($0.50)	($0.44)	($0.49)	($0.37)	($0.45)	($0.49)	($0.52)
Weighted Average Basic Shares Outstanding	39.58M	39.66M	45.09M	45.65M	57.40M	51.45M	67.35M	70.35M	70.54M	69.73M
Diluted Earnings per Share	($0.63)	($0.52)	($0.53)	($0.50)	($0.44)	($0.49)	($0.37)	($0.45)	($0.49)	($0.52)
Weighted Average Diluted Shares Outstanding	39.58M	39.66M	45.09M	45.65M	57.40M	51.45M	67.35M	70.35M	70.54M	69.73M
Weighted Average Basic & Diluted Shares Outstanding	39.58M	45.09M	45.09M	54.53M	54.55M	67.38M	67.42M	70.54M	70.57M	71.03M

This table details how cash moves in and out of ORIC Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-159	-43	36
Net Cash From Operating Activities	-75	-86	-113
Net Cash From Continuing Operating Activities	-75	-86	-113
Net Income / (Loss) Continuing Operations	-89	-101	-128
Consolidated Net Income / (Loss)	-89	-101	-128
Depreciation Expense	0.97	1.03	1.11
Amortization Expense	-1.04	-6.17	-8.10
Non-Cash Adjustments To Reconcile Net Income	15	15	20
Changes in Operating Assets and Liabilities, net	-0.45	4.90	1.97
Net Cash From Investing Activities	-109	-43	22
Net Cash From Continuing Investing Activities	-109	-43	22
Purchase of Property, Plant & Equipment	-2.08	-0.85	-1.19
Purchase of Investments	-238	-239	-252
Sale and/or Maturity of Investments	131	197	275
Net Cash From Financing Activities	25	86	127
Net Cash From Continuing Financing Activities	25	86	127
Repayment of Debt	-0.40	-0.23	-0.17
Issuance of Common Equity	26	86	126
Other Financing Activities, net	0.08	0.06	0.63

This table details how cash moves in and out of ORIC Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-20	38	-7.85	45	-77	-2.85	33	-6.53	-5.60	15
Net Cash From Operating Activities	-19	-15	-21	-21	-20	-24	-30	-26	-29	-28
Net Cash From Continuing Operating Activities	-19	-15	-21	-21	-20	-24	-30	-26	-29	-28
Net Income / (Loss) Continuing Operations	-25	-21	-24	-23	-25	-28	-25	-32	-35	-36
Consolidated Net Income / (Loss)	-25	-21	-24	-23	-25	-28	-25	-32	-35	-36
Depreciation Expense	0.22	0.25	0.25	0.26	0.26	0.26	0.26	0.27	0.27	0.30
Amortization Expense	-0.37	-0.62	-0.86	-1.26	-1.92	-2.12	-2.23	-2.30	-1.95	-1.63
Non-Cash Adjustments To Reconcile Net Income	3.29	3.17	3.61	3.83	3.86	3.94	4.96	5.00	5.06	5.20
Changes in Operating Assets and Liabilities, net	2.37	2.72	0.31	-1.03	3.63	1.98	-8.17	3.37	2.39	4.38
Net Cash From Investing Activities	-0.69	28	13	-19	-58	21	-62	18	23	43
Net Cash From Continuing Investing Activities	-0.69	28	13	-19	-58	21	-62	18	23	43
Purchase of Property, Plant & Equipment	-0.40	-0.29	-0.31	-0.41	-0.08	-0.06	-0.22	-0.33	-0.42	-0.22
Purchase of Investments	-61	-32	-43	-56	-111	-29	-114	-49	-54	-35
Sale and/or Maturity of Investments	61	60	56	37	53	50	53	68	78	78
Net Cash From Financing Activities	0.00	25	0.00	85	0.03	0.45	125	0.82	0.13	0.58
Net Cash From Continuing Financing Activities	0.00	25	0.00	85	0.03	0.45	125	0.82	0.13	0.58
Issuance of Common Equity	-	25	0.00	85	-	0.43	125	0.52	-	0.56
Other Financing Activities, net	0.00	0.00	0.00	-	0.03	0.03	0.20	0.29	0.13	0.01

This table presents ORIC Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	247	252	274
Total Current Assets	210	213	262
Cash & Equivalents	67	23	59
Short-Term Investments	139	185	197
Prepaid Expenses	4.19	4.41	6.29
Plant, Property, & Equipment, net	3.25	2.86	2.92
Total Noncurrent Assets	33	37	8.97
Long-Term Investments	22	27	0.00
Other Noncurrent Operating Assets	12	9.70	8.97
Total Liabilities & Shareholders' Equity	247	252	274
Total Liabilities	25	28	31
Total Current Liabilities	15	20	25
Accounts Payable	1.32	0.94	1.55
Accrued Expenses	14	20	23
Total Noncurrent Liabilities	9.44	7.46	6.17
Other Noncurrent Operating Liabilities	9.44	7.46	6.17
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	222	224	243
Total Preferred & Common Equity	222	224	243
Preferred Stock	0.00	0.00	0.00
Total Common Equity	222	224	243
Common Stock	558	659	806
Retained Earnings	-334	-435	-563
Accumulated Other Comprehensive Income / (Loss)	-1.29	0.26	0.38

This table presents ORIC Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	238	227	292	274	351	329	302
Total Current Assets	199	193	268	232	324	295	279
Cash & Equivalents	29	59	104	26	56	50	44
Short-Term Investments	165	131	160	201	260	237	228
Prepaid Expenses	5.03	3.54	4.20	4.94	7.31	8.19	7.06
Plant, Property, & Equipment, net	3.05	3.11	3.25	3.06	2.80	2.88	3.09
Total Noncurrent Assets	36	30	20	39	24	31	20
Long-Term Investments	24	19	9.58	29	15	22	10.00
Other Noncurrent Operating Assets	12	11	11	10	9.21	9.30	9.55
Total Liabilities & Shareholders' Equity	238	227	292	274	351	329	302
Total Liabilities	23	24	23	27	22	27	28
Total Current Liabilities	13	15	15	19	15	20	21
Accounts Payable	1.53	1.93	3.19	3.74	2.99	2.31	4.25
Accrued Expenses	12	13	11	15	12	17	17
Total Noncurrent Liabilities	9.89	8.97	8.48	7.98	6.93	6.97	6.83
Other Noncurrent Operating Liabilities	9.89	8.97	8.48	7.98	6.93	6.97	6.83
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	215	203	269	247	329	302	274
Total Preferred & Common Equity	215	203	269	247	329	302	274
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	215	203	269	247	329	302	274
Common Stock	530	561	650	654	789	795	800
Retained Earnings	-313	-358	-381	-407	-460	-492	-526
Accumulated Other Comprehensive Income / (Loss)	-1.75	-0.50	-0.57	-0.37	-0.16	-0.26	0.72

This table displays calculated financial ratios and metrics derived from ORIC Pharmaceuticals' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-19.88%	-26.21%	-29.31%
EBIT Growth	-16.37%	-20.72%	-28.99%
NOPAT Growth	-16.35%	-20.72%	-28.99%
Net Income Growth	-13.22%	-12.99%	-26.96%
EPS Growth	-8.70%	12.89%	6.63%
Operating Cash Flow Growth	-26.20%	-14.03%	-31.48%
Free Cash Flow Firm Growth	-27.32%	-10.21%	-35.43%
Invested Capital Growth	20.53%	-86.50%	-17.23%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-0.07%	-10.27%	-5.35%
EBIT Q/Q Growth	0.74%	-9.17%	-6.04%
NOPAT Q/Q Growth	0.74%	-9.17%	-6.04%
Net Income Q/Q Growth	2.11%	-8.03%	-6.65%
EPS Q/Q Growth	2.60%	1.51%	-1.67%
Operating Cash Flow Q/Q Growth	1.26%	-11.65%	-3.48%
Free Cash Flow Firm Q/Q Growth	1.13%	-10.75%	-3.63%
Invested Capital Q/Q Growth	-86.41%	-25.17%	-53.33%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	97.12%	90.90%	89.47%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-35.99%	-45.11%	-54.73%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-35.99%	-45.11%	-54.73%
Return on Equity Simple (ROE_SIMPLE)	-40.08%	-44.94%	-52.59%
Net Operating Profit after Tax (NOPAT)	-64	-78	-100
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-9.79%	-9.99%	-11.33%
Return On Investment Capital (ROIC_SIMPLE)	-	-34.61%	-41.14%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-92	-111	-143
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-92	-116	-150
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.05	2.24	2.34
Price to Tangible Book Value (P/TBV)	1.05	2.24	2.34
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.03	-1.04	-1.05
Leverage Ratio	1.10	1.12	1.13
Compound Leverage Factor	1.07	1.02	1.01
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	3.46	7.83	7.46
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	13.68	10.39	10.56
Quick Ratio	13.40	10.18	10.30
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-66	-72	-98
Operating Cash Flow to CapEx	-3,616.12%	-10,092.82%	-9,483.33%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-5.87	-11	-13
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	1.52	-5.08	-1.89
Enterprise Value (EV)	4.88	267	314
Market Capitalization	233	502	569
Book Value per Share	$5.62	$4.11	$3.45
Tangible Book Value per Share	$5.62	$4.11	$3.45
Total Capital	222	224	243
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-228	-235	-256
Capital Expenditures (CapEx)	2.08	0.85	1.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-16	-19
Debt-free Net Working Capital (DFNWC)	195	192	237
Net Working Capital (NWC)	195	192	237
Net Nonoperating Expense (NNE)	25	23	28
Net Nonoperating Obligations (NNO)	-228	-235	-256
Total Depreciation and Amortization (D&A)	-0.08	-5.14	-7.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.25)	($1.96)	($1.83)
Adjusted Weighted Average Basic Shares Outstanding	39.66M	51.45M	69.73M
Adjusted Diluted Earnings per Share	($2.25)	($1.96)	($1.83)
Adjusted Weighted Average Diluted Shares Outstanding	39.66M	51.45M	69.73M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	45.09M	67.38M	71.03M
Normalized Net Operating Profit after Tax (NOPAT)	-64	-78	-100
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ORIC Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-44.31%	-0.29%	-14.46%	-26.54%	-17.43%	-48.00%	-17.77%	-46.33%	-31.79%	-22.87%
EBIT Growth	-39.22%	3.01%	-10.41%	-20.76%	-11.63%	-42.09%	-12.90%	-44.11%	-33.60%	-25.91%
NOPAT Growth	-39.22%	3.01%	-10.41%	-20.76%	-11.63%	-42.09%	-12.90%	-44.11%	-33.60%	-25.91%
Net Income Growth	-34.75%	8.45%	-3.39%	-13.10%	-2.61%	-35.89%	-4.45%	-39.31%	-35.67%	-28.16%
EPS Growth	-34.04%	10.34%	10.17%	1.96%	30.16%	5.77%	30.19%	10.00%	-11.36%	-6.12%
Operating Cash Flow Growth	-59.12%	5.86%	9.20%	-18.95%	-1.68%	-58.33%	-46.34%	-21.19%	-46.59%	-15.59%
Free Cash Flow Firm Growth	-93.58%	-37.12%	1.69%	16.85%	26.78%	0.47%	-57.61%	-77.55%	-87.86%	-52.55%
Invested Capital Growth	36.22%	20.53%	-96.35%	-410.87%	-177.75%	-86.50%	53.85%	-24.26%	4.30%	-17.23%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-25.80%	12.97%	-16.87%	1.10%	-16.74%	-9.69%	7.01%	-22.89%	-5.13%	-2.27%
EBIT Q/Q Growth	-24.15%	13.91%	-16.09%	2.67%	-14.76%	-9.57%	7.76%	-24.24%	-6.39%	-3.27%
NOPAT Q/Q Growth	-24.15%	13.91%	-16.09%	2.67%	-14.76%	-9.57%	7.76%	-24.24%	-6.39%	-3.27%
Net Income Q/Q Growth	-22.39%	16.04%	-14.86%	4.18%	-11.04%	-11.19%	11.72%	-27.80%	-8.14%	-5.04%
EPS Q/Q Growth	-23.53%	17.46%	-1.92%	5.66%	12.00%	-11.36%	24.49%	-21.62%	-8.89%	-6.12%
Operating Cash Flow Q/Q Growth	-8.69%	20.66%	-34.57%	-2.51%	7.09%	-23.54%	-24.38%	15.11%	-12.38%	2.58%
Free Cash Flow Firm Q/Q Growth	-21.57%	14.03%	11.95%	9.64%	-7.05%	-16.87%	-39.43%	-1.79%	-13.26%	5.10%
Invested Capital Q/Q Growth	-226.09%	-86.41%	-4.33%	19.44%	-77.28%	-25.17%	74.19%	-116.91%	-36.55%	-53.33%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.63%	94.25%	93.25%	91.81%	88.83%	90.14%	86.27%	88.74%	90.21%	91.75%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-35.96%	-35.99%	-39.44%	-36.61%	-40.33%	-45.11%	-38.30%	-38.79%	-45.98%	-54.73%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-35.96%	-35.99%	-39.44%	-36.61%	-40.33%	-45.11%	-38.30%	-38.79%	-45.98%	-54.73%
Return on Equity Simple (ROE_SIMPLE)	-42.38%	0.00%	-44.33%	-34.44%	-37.68%	0.00%	-30.96%	-36.63%	-43.75%	0.00%
Net Operating Profit after Tax (NOPAT)	-18	-15	-18	-17	-20	-22	-20	-25	-27	-28
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-2.66%	-2.11%	-2.57%	-2.13%	-2.28%	-2.73%	-1.75%	-2.32%	-2.88%	-3.51%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-9.82%	-	-	-	-11.39%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-26	-22	-26	-25	-29	-31	-29	-36	-38	-40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-26	-22	-26	-26	-30	-33	-31	-38	-40	-41
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.59	1.05	1.27	1.30	1.33	2.24	2.82	1.58	2.64	2.34
Price to Tangible Book Value (P/TBV)	0.59	1.05	1.27	1.30	1.33	2.24	2.82	1.58	2.64	2.34
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.03	-1.02	-1.01	-1.03	-1.04	-1.02	-1.02	-1.03	-1.05
Leverage Ratio	1.09	1.10	1.10	1.09	1.11	1.12	1.09	1.09	1.11	1.13
Compound Leverage Factor	1.05	1.04	1.03	1.00	0.98	1.01	0.94	0.96	1.00	1.03
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	2.01	4.39	4.83	8.05	5.87	8.87	24.05	9.34	13.62	8.70
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	14.96	13.68	12.99	18.46	12.26	10.39	21.31	15.08	13.15	10.56
Quick Ratio	14.58	13.40	12.76	18.18	12.00	10.18	20.83	14.66	12.82	10.30
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-17	-15	-14	-14	-17	-24	-24	-27	-26
Operating Cash Flow to CapEx	-4,817.96%	-5,341.12%	-6,654.19%	-5,220.99%	-25,512.99%	-42,578.95%	-13,846.79%	-7,695.20%	-6,889.23%	-12,810.05%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-3.15	-5.87	-6.13	-4.94	-8.75	-11	-2.83	-6.13	-8.37	-13
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	1.79	1.52	-3.01	-3.97	-5.60	-5.08	3.30	-1.20	0.38	-1.89
Enterprise Value (EV)	-91	4.88	48	76	74	267	595	168	441	314
Market Capitalization	127	233	257	350	330	502	926	477	723	569
Book Value per Share	$5.43	$5.62	$4.50	$5.96	$4.54	$4.11	$4.88	$4.49	$3.88	$3.45
Tangible Book Value per Share	$5.43	$5.62	$4.50	$5.96	$4.54	$4.11	$4.88	$4.49	$3.88	$3.45
Total Capital	215	222	203	269	247	224	329	302	274	243
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-218	-228	-209	-274	-256	-235	-331	-309	-282	-256
Capital Expenditures (CapEx)	0.40	0.29	0.31	0.41	0.08	0.06	0.22	0.33	0.42	0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-8.26	-11	-11	-10	-14	-16	-7.91	-11	-14	-19
Debt-free Net Working Capital (DFNWC)	185	195	178	254	213	192	309	275	258	237
Net Working Capital (NWC)	185	195	178	254	213	192	309	275	258	237
Net Nonoperating Expense (NNE)	6.84	5.36	5.97	5.45	5.40	6.33	4.72	6.75	7.74	8.61
Net Nonoperating Obligations (NNO)	-218	-228	-209	-274	-256	-235	-331	-309	-282	-256
Total Depreciation and Amortization (D&A)	-0.15	-0.37	-0.61	-1.00	-1.67	-1.86	-1.97	-2.02	-1.68	-1.33
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.63)	($0.52)	($0.53)	($0.50)	($0.44)	($0.49)	($0.37)	($0.45)	($0.49)	($0.52)
Adjusted Weighted Average Basic Shares Outstanding	39.58M	39.66M	45.09M	45.65M	57.40M	51.45M	67.35M	70.35M	70.54M	69.73M
Adjusted Diluted Earnings per Share	($0.63)	($0.52)	($0.53)	($0.50)	($0.44)	($0.49)	($0.37)	($0.45)	($0.49)	($0.52)
Adjusted Weighted Average Diluted Shares Outstanding	39.58M	39.66M	45.09M	45.65M	57.40M	51.45M	67.35M	70.35M	70.54M	69.73M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.58M	45.09M	45.09M	54.53M	54.55M	67.38M	67.42M	70.54M	70.57M	71.03M
Normalized Net Operating Profit after Tax (NOPAT)	-18	-15	-18	-17	-20	-22	-20	-25	-27	-28
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About ORIC Pharmaceuticals' Financials

When does ORIC Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, ORIC Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has ORIC Pharmaceuticals' net income changed over the last 2 years?

ORIC Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$127.85 million in 2024, rising from -$89.12 million in 2022. The previous period was -$100.70 million in 2023.

What is ORIC Pharmaceuticals's operating income?

ORIC Pharmaceuticals's total operating income in 2024 was -$142.90 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $142.90 million

How has ORIC Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, ORIC Pharmaceuticals' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does ORIC Pharmaceuticals have?

ORIC Pharmaceuticals' total liabilities were at $31.02 million at the end of 2024, a 11.1% increase from 2023, and a 24.9% increase since 2022.

How much cash does ORIC Pharmaceuticals have?

In the past 2 years, ORIC Pharmaceuticals' cash and equivalents has ranged from $23.38 million in 2023 to $66.84 million in 2022, and is currently $59.41 million as of their latest financial filing in 2024.

How has ORIC Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, ORIC Pharmaceuticals' book value per share changed from 5.62 in 2022 to 3.45 in 2024, a change of -38.7%.

Related Companies

This page (NASDAQ:ORIC) was last updated on 4/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ORIC Pharmaceuticals (ORIC) Financials

Frequently Asked Questions About ORIC Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ORIC Pharmaceuticals (ORIC) Financials

Annual Income Statements for ORIC Pharmaceuticals

Quarterly Income Statements for ORIC Pharmaceuticals

Annual Cash Flow Statements for ORIC Pharmaceuticals

Quarterly Cash Flow Statements for ORIC Pharmaceuticals

Annual Balance Sheets for ORIC Pharmaceuticals

Quarterly Balance Sheets for ORIC Pharmaceuticals

Annual Metrics and Ratios for ORIC Pharmaceuticals

Quarterly Metrics and Ratios for ORIC Pharmaceuticals

Frequently Asked Questions About ORIC Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools